Please confirm that you would like to log out of Medscape.
If you log out, you will be required to enter your username and password the next time you visit.
Log outCancel
EHAHodgkin's Tx Intensity Can Be Spared With Negative PETPatients with advanced Hodgkin's lymphoma who show early metabolic response on FDG-PET scans can safely and effectively be switched to a reduced chemotherapy regimen, say researchers.
Latest Daratumumab Results Herald 'New Era' in MyelomaAnother daratumumab trial shows benefit in relapsed myeloma, with the highest response rates ever seen; the findings herald
a 'new era of immunotherapies,' says expert.
Medscape Medical News, Jun 13, 2016
Blinatumomab Beats Chemo for R/R ALL: Survival DoubledThe single-agent immunotherapy was superior to chemotherapy in relapsed/refractory acute lymphoblastic leukemia, almost doubling
overall survival in the phase 3 TOWER trial.
Medscape Medical News, Jun 16, 2016
CML Remissions Continue Even After TKI Drugs Are StoppedDuration of tyrosine kinase inhibitor (TKI) treatment and molecular response have been identified as key predictors of sustained
remission after the discontinuation of TKIs.
